scispace - formally typeset
S

Stefan Isenmann

Researcher at University of Jena

Publications -  102
Citations -  6769

Stefan Isenmann is an academic researcher from University of Jena. The author has contributed to research in topics: Retinal ganglion & Retina. The author has an hindex of 39, co-authored 101 publications receiving 6495 citations. Previous affiliations of Stefan Isenmann include University of Zurich & University of Göttingen.

Papers
More filters
Journal ArticleDOI

Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud.

TL;DR: It is reported that the c-met-encoded receptor tyrosine kinase is essential for migration of myogenic precursor cells into the limb anlage and for migration into diaphragm and tip of tongue.
Journal ArticleDOI

Normal host prion protein necessary for scrapie-induced neurotoxicity

TL;DR: In addition to being resistant to scrapie infection, brain tissue devoid of PrPc is not damaged by exogenous PrPSc, and even 16 months after inoculation no pathological changes were seen in PrP-deficient tissue, not even in the immediate vicinity of the grafts.
Journal ArticleDOI

Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas

TL;DR: The first functional evidence that MCP‐1 recruits microglial cells to gliomas and promotes their growth in vivo is provided, suggesting that microglia cells may support rather than suppress glioma growth.
Journal ArticleDOI

Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity.

TL;DR: It is reported that the locoregional application of Apo2 ligand (Apo2L) exerts strong antitumor activity on preestablished intracranially growing human U87MG glioma xenografts in athymic mice and proposed that a phase 1 trial of intralesional Apo 2L therapy for human glioblastoma multiforme is warranted.
Journal Article

Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis.

TL;DR: It is reported that DcR3 is expressed by the majority of long-term and ex vivo malignant glioma cell lines as well as in human glioblastoma in vivo and Chemotaxis assays revealed that D cR3 counteracts the chemotactic activity of CD95L against microglial cells in vitro.